atopic dermatitis eczema psoriasis
Conditions
Interventions
None listed
Sponsors
Universitair Medisch Centrum Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Atopic dermatitis patients: - Adult (18-70 years) male or female patients diagnosed with atopic dermatitis - Biopsy location (4x4 cm) should not be treated with topical steroids, dithranol or vitamin D3 preparations for at least 1 week;Psoriasis vulgaris patients: - Adult (18-70 years) male or female patients diagnosed with psoriasis vulgaris - Biopsy location (4x4 cm) should not be treated with topical steroids, dithranol or vitamin D3 preparations for at least 1 week;Healthy controls: - Adult (18-70 years) male or female volunteers without a history of skin diseases - Biopsy location (4x4 cm) should not be treated with topical steroids, dithranol or vitamin D3 preparations for at least 1 week - No history of asthma and/or hay fever and/or house dust mite allergy;Patients undergoing plastic surgery: - Adult (18-70 years of age) male or female patients without a history of skin diseases - No history of asthma and/or hay fever and/or house dust mite allergy
Exclusion criteria
Exclusion criteria: - Use of systemic immunosuppressive drugs (i.e., cyclosporin, prednisolone, methotrexate, neotigasone, fumaric acid) in the 6 weeks prior to inclusion - Exposure of biopsy location to (extraordinary) UV sunlight (i.e. UV-therapy, sunny holiday) in the weeks prior to inclusion - (Secondary) skin infection
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Suppressive capacity of Tregs measured as suppression of proliferation by effector T cells (Teffs) (Tregs and Teffs will be co-cultured in the presence of antigen presenting cells. Teffs will be labeled with CFSE. Dilution of CFSE is a measure for proliferation) | — |
Countries
Netherlands
Outcome results
None listed